Researchers showed that, dasatinib in melanoma stimulated its proper mechanism of resistance, independently of MAPK and PI3K/AKT pathway reactivation commonly associated to secondary c-Kit mutations, but through CRTC3/MITF/Bcl-2 pathway activation at clinically relevant doses.
[Molecular Cancer Research]
6606345
{6606345:CHKUCJYE}
apa
50
1
160364
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-1e6c9ec87f48897d0a6344f301ec26e1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CHKUCJYE%22%2C%22library%22%3A%7B%22id%22%3A6606345%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sabbah%20et%20al.%22%2C%22parsedDate%22%3A%222021-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESabbah%2C%20M.%2C%20Krayem%2C%20M.%2C%20Najem%2C%20A.%2C%20Sales%2C%20F.%2C%20Miller%2C%20W.%2C%20Rincon%2C%20S.%20del%2C%20Awada%2C%20A.%2C%20Ghanem%2C%20G.%20E.%2C%20%26amp%3B%20Journe%2C%20F.%20%282021%29.%20Dasatinib%20stimulates%20its%20own%20mechanism%20of%20resistance%20by%20activating%20a%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20in%20melanoma%20with%20mutant%20or%20amplified%20c-Kit.%20%3Ci%3EMolecular%20Cancer%20Research%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-20-1040%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1541-7786.MCR-20-1040%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6606345%26amp%3Bitem_key%3DCHKUCJYE%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dasatinib%20stimulates%20its%20own%20mechanism%20of%20resistance%20by%20activating%20a%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20in%20melanoma%20with%20mutant%20or%20amplified%20c-Kit%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malak%22%2C%22lastName%22%3A%22Sabbah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%22%2C%22lastName%22%3A%22Krayem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Najem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wilson%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%20del%22%2C%22lastName%22%3A%22Rincon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Awada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghanem%20E.%22%2C%22lastName%22%3A%22Ghanem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Journe%22%7D%5D%2C%22abstractNote%22%3A%22Amplification%20or%20activating%20mutations%20of%20c-Kit%20are%20a%20frequent%20oncogenic%20alteration%20that%20occurs%20commonly%20in%20acral%20and%20mucosal%20melanoma.%20Among%20c-Kit%20inhibitors%2C%20dasatinib%20is%20the%20most%20active%20due%20to%20its%20ability%20to%20bind%20both%20active%20and%20inactive%20conformations%20of%20the%20receptor.%20However%2C%20its%20use%20as%20a%20single%20agent%20in%20melanoma%20showed%20limited%20clinical%20benefit.%20We%20first%20found%20that%20sensitivity%20to%20dasatinib%20is%20restricted%20to%20melanoma%20cell%20lines%20harbouring%20c-Kit%20alteration%20but%2C%20unexpectedly%2C%20we%20observed%20lower%20effect%20at%20higher%20concentrations%20that%20can%20readily%20be%20found%20in%20patient%20blood.%20We%20then%20investigated%20relevant%20pathway%20alterations%20and%20found%20complete%20inhibition%20of%20MAPK%20and%20PI3K%5C%2FAKT%20pathways%20but%20an%20increase%20in%20MITF%20and%20its%20downstream%20target%20Bcl-2%20through%20CRTC3%20pathway%20which%20turn%20on%20the%20CREB%20regulated%20transcription%20of%20MITF.%20More%20importantly%2C%20dasatinib%20up-regulates%20MITF%20and%20Bcl-2%20through%20SIK2%20inhibition%20revealed%20by%20CRTC3%20reduced%20phosphorylation%2C%20CREB%20transcription%20activation%20of%20MITF%2C%20MITF%20transcription%20activation%20of%20Bcl-2%20as%20well%20as%20pigmentation.%20Furthermore%2C%20overexpression%20of%20MITF%20renders%20melanoma%20cells%20resistant%20to%20all%20dasatinib%20concentrations.%20Selective%20Bcl-2%20inhibition%20by%20ABT-199%20or%20Bcl-2%20knock%20out%20restores%20the%20sensitivity%20of%20melanoma%20cells%20to%20dasatinib%2C%20validating%20the%20involvement%20of%20MITF%20and%20Bcl-2%20axis%20in%20the%20resistance%20of%20melanoma%20to%20dasatinib.%20In%20conclusion%2C%20we%20showed%20for%20the%20first%20time%20that%2C%20dasatinib%20in%20melanoma%20stimulate%20its%20proper%20mechanism%20of%20resistance%2C%20independently%20of%20MAPK%20and%20PI3K%5C%2FAKT%20pathway%20reactivation%20commonly%20associated%20to%20secondary%20c-Kit%20mutations%2C%20but%20through%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20activation%20at%20clinically%20relevant%20doses%20which%20may%20explain%20the%20weak%20clinical%20benefit%20of%20dasatinib%20in%20melanoma%20patients.%20Implications%3A%20Dasatinib%20stimulates%20its%20proper%20mechanism%20of%20resistance%20through%20CRTC3%5C%2FMITF%5C%2FBcl-2%20pathway%20which%20may%20explain%20its%20modest%20clinical%20efficiency%20in%20melanoma%20patients%22%2C%22date%22%3A%222021%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1541-7786.MCR-20-1040%22%2C%22ISSN%22%3A%221541-7786%2C%201557-3125%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fmcr.aacrjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2021%5C%2F03%5C%2F19%5C%2F1541-7786.MCR-20-1040%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-03-22T22%3A12%3A44Z%22%7D%7D%5D%7D
Sabbah, M., Krayem, M., Najem, A., Sales, F., Miller, W., Rincon, S. del, Awada, A., Ghanem, G. E., & Journe, F. (2021). Dasatinib stimulates its own mechanism of resistance by activating a CRTC3/MITF/Bcl-2 pathway in melanoma with mutant or amplified c-Kit. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.MCR-20-1040 Cite
